Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1.
Immunization with a recombinant glycoprotein 160 envelope immunogen derived from a virus of genetic subtype B induced strong specific T-helper cell responses in asymptomatic human immunodeficiency virus (HIV) carriers infected with subtypes B to G. This indicates that the HIV-specific T-helper immunity, which is the basis for development of antibodies and cytotoxic T lymphocytes, can be improved by both homologous and heterologous antigens. It also suggests that a particular immunogen can be effective against many different HIV strains.
Leandersson
A C
AC
Karolinska Institute, Swedish Institute for Infectious Disease Control, S-171 82 Solna, Sweden. Ann-Charlotte.Leandersson@smi.ki.se
Gilljam
G
G
Fredriksson
M
M
Hinkula
J
J
Alaeus
A
A
Lidman
K
K
Albert
J
J
Bratt
G
G
Sandström
E
E
Wahren
B
B
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D003429:Cross Reactions; D019302:HIV Envelope Protein gp160 / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000145:classification / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D016915:AIDS Vaccines; D019302:HIV Envelope Protein gp160; D014614:Vaccines, Synthetic; C053473:VaxSyn HIV-1 (gp160) vaccine